Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

Xenon ( ($XENE) ) has issued an update. Xenon Pharmaceuticals will showcase new Phase 3 and long-term data for its lead candidate azetukalner in fo...

Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting

In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Xenon, with a price target of $74.00. According to Tip...

H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)

Xenon Pharmaceuticals ($XENE) announced an update on their ongoing clinical study. Xenon Pharmaceuticals Inc. (XENE) has completed its Phase 3 X-TO...

Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Xenon on March 9 and set a price target of $77.00. The company’s share...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$58.59	0.00%	764.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$58.59	0%	764.47K
3
4
5
6

XENE

XENE

No Data Available

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel